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At present, China's pharmaceutical industry is in a state of structural imbalance.
With the development of China's market economy and capital market, mergers and
acquisitions (M&A) have become an important way for the reform of the
pharmaceutical industry. M&A can improve the overall performance of enterprises.
The year of 2012 is a turning point in the development of China's pharmaceutical
industry, and the industry environment has changed significantly different from the
past. Under the new stage, whether the performance of M&A has new characteristics,
the related research is still in the blank. At the same time, the past for the analysis of
factors affecting the performance of M&A mainly focus on the micro level. The
impact of macroeconomic policy issues, especially for China's pharmaceutical market
under the guidance of the state, is also very important.
Based on reviewing the summary of historical documents, this article takes
China's 2012 -2013 year between 64 listed pharmaceutical enterprises merger cases as
samples, and uses the financial indicators and multi factor analysis method to carry
out empirical research. Then, it explores the influencing factors from micro and macro
aspects, and draws the following conclusions:
Firstly, the comprehensive performance of the enterprises deteriorated in the first
year after the merger significantly, and got recovery and improvement until the next
three years. Secondly, we can see from the micro aspect: (1)Enterprises holding has a
more positive effect on China's pharmaceutical companies, and the performance can
be significantly improved in the third year. (2) Vertical merger can obtain better
performance in third years, and the difference was significant, while the horizontal
merger performance in first year has deteriorated significantly. (3)The performance of
non-cash payment of M & A has been significantly improved in the next three years,
compared to cash payment behavior. Thirdly, from the macro level: (1) The price
trend of bidding to speed up the pace of industry consolidation, and easily lead to
enterprises in the lowest bid while the excessive pursuit of short-term benefits. (2)














integration for the purpose of mergers and acquisitions.The empirical research shows
that technology mergers and acquisitions is not only conducive to significantly
enhance the company's overall technical strength, but also can significantly improve
the consolidated financial performance.
Finally, according to the conclusions of the research, some suggestions about the
pharmaceutical industry are put forward.
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也同样不乐观，在 2011 年提前一年出现拐点。（如图 1.1-1.2）
















图 1.2 2009-2015 年我国医药行业销售利润增速水平
资料来源：wind，2016 年
2、医保基金收支增速出现拐点，面临入不敷出























发生的并购事件有 101 起，到 2015 年已增加到 244 起；涉及的金额也越来越大：
2012 年并购总金额为 588 亿人民币，截至 2015 年，扩大了 2.38 倍，接近 1400
亿。特别是进入 2014 年，每月均有过亿甚至几十亿的并购事件。
图 1.4 2011-2015 年我国医药行业并购数量和金额 单位：亿元
资料来源：wind，2016 年
表 1.1 2014 年底-2015 年中医药并购大事记
时间 并购企业 事件
2014 年 10 月 贵州益佰 4.84 亿收购长安国际 72%股权
2014 年 11 月 亚太药业 1.69 亿出售 9.8%股权
2014 年 12 月 上海莱士 47.58 亿收购同路生物 89%股权
2015 年 1 月 誉衡药业 23.89 亿收购普德药业
2015 年 2 月 凯利泰 1.7 亿收购易生科技 27%股权
2015 年 3 月 宁波药材 1亿出售 64%股权
2015 年 4 月 启迪控股 6.4 亿收购紫光古汉 18%股权
2015 年 5 月 双成药业 14.67 亿收购澳亚生物

























也越来越多，来自 2015 年 IMS 的数据，现金支付虽然占据主导，占比 82%，股





















图 1.6 2015 年我国医药企业并购支付类型分类
资料来源：wind，2016 年
第 2 节 研究意义
从上世纪 90 年代开始医药产业链的搭建，到 2006 年生产企业执行全面 GMP
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